Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma

Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we tested the effect of three IGF s...

Full description

Bibliographic Details
Main Authors: Olaf Beck, Claudia Paret, Alexandra Russo, Jürgen Burhenne, Margaux Fresnais, Kevin Steimel, Larissa Seidmann, Daniel-Christoph Wagner, Nadine Vewinger, Nadine Lehmann, Maximilian Sprang, Nora Backes, Lea Roth, Marie Astrid Neu, Arthur Wingerter, Nicole Henninger, Khalifa El Malki, Henrike Otto, Francesca Alt, Alexander Desuki, Thomas Kindler, Joerg Faber
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
osteosarcoma
ceritinib
dasatinib
Online Access:https://www.mdpi.com/2072-6694/12/4/793

Similar Items

Similar Items